the execution million included joining a ended morning, Good you of quarter, thank quarter from RedWave solid technology, $XX million, growth of earnings XXXX Kelly. year-over-year.
This on with $X.X Thanks, which XX% we call. representing and of multitude fronts We XX. we delivered second the revenue acquired our second in on for April quarter revenue and
for identification forensics handheld MXXXX portfolio mass for devices complementing expanded RedWave have chemical add workflows. to analysis both excited handheld an our commercial engine, of detection.
We devices to are chemical trace now spec chemical for We our
our for point recurring first the demonstrated year, half Our as XX% by revenues. customers consistent need revenue, of offerings the value representing of our which of
in Our always from forensics analysis goal control win the characterization. chemical to biopharma life-altering has point-of-need to been and process applications
is Our quarter measurable. progress goal towards that in the
XX quickly we CRM of for handheld During Explorer the devices.
Overall, integration. devices to website including product in want a Also, quarter, that for RedWave included our to and Devices integration commercial RedWave team the enthusiasm received technology, and same and total MXXXX teams and our their bring sales sold first RedWave our relentless multisystem I our completed in result. plus training both work for and the XXX they order, the the customer team into tremendous the thank in as momentum XXX created total we quarter. devices have
Michelle former and support young is further illegal market. brings the We the determined in efforts forensics extensive adults.
She Administration knowledge Board against Directors. a administrator advocate our Unfortunate welcomed Drug passionate also drugs government substance of to recently experience, leader penetrate of to Leonhart, which fight and prevention for the will and abuse US Michele a our
persisted, focus instrumentation continue building For technologies bioprocessing ongoing and to continue and adopting the pressures serves macro we conservatism towards our to we see that desktop well science CapEx and pressures, foundation that for on an position have a market, portfolio market will innovative spending.
Despite overall us a life future.
on and our share shortly. the cell more in innovators I'll space, hardware with partnerships pursuing aggressively here are progress We therapy
integrations this year. sensor. as and last a upgrades simplifying the to to As hardening enable process technology present our and devices on focused includes we're desktop launched products year, simple our to we X existing ultimate capability developments with new goal This
are software introduced device's routine been XXXX, now use customer pharma noting to For device use support positive in REBEL key its manufacturing we Feedback development and with optimizing that addition initial labs. hardware our one customers. they has the to current testing REBEL and plan process have with for in begun
are We product in customers' our appreciative and truly support of input improvements. enhancements these and
objective, on during have to we X the like areas the second I'd our Now, provide quarter. focus with across more first our progress market made expansion. Starting detail
is market accounts. partnerships enterprise fostering outreach our strategic key to accounts, by expand engaging with reach extending Our global focus and across new our
protect handheld choose devices public our are especially vapors to gases, and proud at concern, unknown identify particular first that chemical Aerosol. ability key events, to hazards. and mission the test public is Of their in the We and responders from infrastructure large
response held local this of robot. mixtures and explorer race and providing the Indianapolis deal can quickly and FTIR was complex Spot our identify Beacon complements by used XXX Republican Convention on the were the by and National both gases and Our events, onto detection MX-XXX at at devices including device thousands at and Dynamics and monitoring levels.
Both Boston team Vapors Explorer vapors, Aerosol of remote trace integrated
have confidence several the addition, in our its the organizations. at these of capital kind technology response and large open-air nation's deployed Beacons monitoring events our we over July partnership leading X were We with value first teams the holiday. In in air the have
Blood cell Quantum desktop launched real-time and the manual expansion control is enables I'm used from process cost Technologies, Quantum our officially Maven cell that and system excited Terumo for Turning Flex glucose our to therapy risk announce hands to that cell lactate cell the that of amount manufacturing. ensure posted time throughout process that real-time monitoring Terumo reduce MAVEN Flex more July, on expansion by through development a system used for automated of tight to and in sampling.
The can have be operators. configuration data maintain Cell without further required BioInsight, portfolio. and control clinical automated noted conditions.
He allows and systems scientist In and over glucose culture sampling lactate noted that webinar reproducibility the like we frequent
Our of leg progress cost goods order respective developers, process the treatments.
Earlier are these accelerate announced this offer personal gain cell excited insights development valuable a our we our year, platform, shovel into bioprocess to ability and teams reduce parameters. to therapy to in manufacturing collaboration in-line EAT with monitoring scalable, integrated, Roman-based MAVERICK, cell MAVERICK cell of Solaris' a therapy analyzer system, solution critical Solaris to integrate control fully provides and real-time for
an continue with batch-to-batch are personalized these simple, devices products a as value desktop directly understanding process our path Solaris with to address for addition critical inflection this Anderson Resilience need for therapies to cell other Terumo, and other automated that novel we handful contribute of integration recently such with for an efficient a a portfolio alliances, joint therapy MD could research engaged is In Center. point to and direct strategy venture entered believe and there and our access to seek as market this. between create our innovators National is hardware enhance our treatments.
It applications, for and into a tools, to of Cancer pursuits.
Despite that we the PAT complements desktop to Ultimately, cost we and CTMC, sales reproducibility and cell ensure our collaboration actively
through step CTMC support aims efficiently the to development journey. and the usher therapies in process development, integrated For every novel seamlessly cell regulatory
is therapy manual a required, labor-intensive cell multiple points time-consuming. there process During for and that are production, sampling which is is
therapies.
We've in GX today's of higher research expanded benefit partnership the and can demonstrate we to an assessment.
At will MAVEN, desktop therapies.
Earlier our Bones, manufacturing, with for Boston also aims bioreactors, the and Maverick for Bioprocessing Dr. includes began solution upcoming product in lactate Summit for and strategic REBEL National for value transformative collaborations standard.
MAVEN providing a lay Bioprocessing and think-ful easy-to-implement our of robust demonstrating year, of is that and continuous the monitoring solutions. is quality the month, foundation Ireland. that how collaboration glucose bioproduction that ultimately vaccines and hands-off make manufacturing and of findings cell more add investigator of informative we efficiency gene present real-time value Research analytics cell rapid collaboration NIBRT's with culture analysis of and Jonathan Rebel outline believe demonstrates to industry manufacturing prostate for NIBRT, of this monitoring and PAT process will at of Our enables behavior for and integrated rapid Training partnerships the Maverick, therapy on an Institute discoveries focus innovative in based recombinant monoclonal solid a revolutionize research this portfolio these data our believe realizing on platform cell in ZipChip ZipChip proteins, to generation and NIBRT lead antibodies.
We
Turning portfolio to engagement. second our objective,
first chemicals. and gases an package frac, materials kind We explorer vapor uses to calls and handheld customers.
In enhanced can Protection for is nearly result maximize identify simultaneously multiple fire product of are per that a Fire leveraging of hazards. opportunities need and for Explorer, as unknown and strengthen such the accurately explorer the quantify, handheld ending pulsifire. X% orders million our and field our technology gas we changer is and of the automatically potential Many firefighters.
According portfolios product detected responders device quantify engagements all Explorer the believe they identify, June, X.X% hazardous and first for approximately compared civilians compounds calls simple to and can at date.
The identify software Agency, airborne X,XXX advanced spectroscopy are its quantification that parts use the are launched in by departments the level. to so to expanded is game of FTR manage to to mitigate analyzer, National effectively with our We
with all drug for mass continue in included drug in that with enabling updated.
Drug X.X evolving which use.
Concerningly, has released A data quarter, additions diligently was spectrometer, new the cathinone include We synthetic more even to be the during easily is drugs software targets and potent MXXXX-handheld X has federal. field recent Version synthetic protein-nitazene. electronically monitor one the and combination it also to in shown nitazene other our been than devices cannabinoids, target identified landscape that of
nitazene, is used identify first handheld the only currently device level. Our that by can MXXXX responders proteins trace
target MXXXX our educating In team drug informing forensic in data released to appear coactions through in a reach-back aware new service, internal trends. and application of making that and analyte and emerging our team the customers software, importantly, chemist of monitors targets addition updates field
the cocaine, gaining substances mostly as opioids, contain aware not as America our it XX/X and have has As to responders first with known such field to mixture the a methamphetamine identify advanced traction while this and became seeing hypercritical an but law that been and [indiscernible] And, other drug US. the an technology is of and now personnel example, seen to in field, team quickly is support illicit team it cocaine, remains paint does that MDMA, reach Latin the and in point, of upgradable cocktail data.
It in in need US cocaine fact, ketamine, current they usually in accurately MXXXX, our such a back as recently stay other Europe enforcement along drugs.
presentations Medicine, and X Turning the the collaborators Research Wisconsin the launch newly of launched specs to noted ASMS, at demonstrate and Mass At to compounds to ASMS can fast for upstream at a spectrometer, at had [indiscernible].
Also showing research the metabolite XXX pairing used device herdiomics accuracy our and over monoclonal We metabolomics, It's X these strong our rate. a NIBRT minutes high-quality technical stellar less a our of pumping Spectrometry ZipChip American concentration or speed with included was quantitative Society exploit precision that or applications June. quantitative and see than for in University oral data.
Results antibody. the desktop. of using wide in speed ZipChip. thermo-scientific great production the of under mass full CE acquisition mass
promising in included the analysis minutes high Our the in presented short resolution articles published time posters, University AstraZeneca, minutes and in review was primary source living energy quarter. the of Journal highlighted Analytica high serves of Pharmaceutical in the Acta, the from the Sciences ZipChip's a Hill.
ZipChip's collaborators in biomedical and that noted the lines a XX several Scientific Journal cells.
In Polpharma of variant at team which for Analytical Neither Chapel North the and selection sensitivity as cell the to journal less biosimilar. publication Amsterdam metabolite from charge data peer analysis, AstraZeneca in Zeneca highlighted than rapid In in of X process ATP, study analysis publication scientific in for during ability scientists the also most scientists in enables Carolina development of Biologics, ZipChip of Center Bio-Techne, Thermo-Fisher also provide which the from separations
high-resolution Pharmaceutical of customer noted we newly enables variance the continue portfolio. that desktop analysis that Scientists, Finally, species conditions, in a our development thus ZipChip's rapid to various of and scientists supporting formulation Journal and biotherapeutics.
Overall, expanded I'm from in process under Regeneron identification publication engagement with pleased of handheld charge stress strengthen
third Finally, our objective, operational excellence.
to We $X financial XXXX. framework revenue path a We've company profitable million growth profile growth to with a acquiring accretive by are to significantly gross identified sustained the that's be in profitability. cost we and enhanced synergies executing than margins, Technology, and realized both annual more in to for RedWave forecasted have our
sales marketing Our overlapping integration the support improved will that commercial is effectively pleased and broader bases margins we in progressing and QX, portfolio scale to call our our smoothly, forensic solutions. revenues early evidence with team managing better of and view and investments. points of our which is and as RedWave's We're customer leverage contribution
revenues breakeven for on leverage RedWave's that expect to hand.
With with further reach call this accelerate we second we'll steeper relationships opportunity that, $XXX in creating on to again, be details and portfolio, to solutions, our for our government complementary annualized financials. we with our breakeven believe path we our ramp Joe flow will our cash half forensics these strategic thereafter. now importantly, accelerate scale.
We existing accounts a I with And As profitability to seasonally the to will over continue to efficiencies cash of with enter over efforts a turn plan to able more strong penetrate crossover million
